Two Cheap, Already-Approved Drugs Stack to Add the Equivalent of ~20 Human Years in Mice

Two Cheap, Already-Approved Drugs Stack to Add the Equivalent of ~20 Human Years in Mice

Linda Partridge's lab went quiet when the numbers came in. Two off-patent, already-prescribed drugs — one originally developed for diabetes, the other for blood pressure — were given together to aging mice. Neither drug alone had done much. Together, they extended lifespan by 30% additively, beyond what any single compound had achieved in comparable trials, and the mice stayed mobile and healthy until near the end.

What makes this genuinely different from the usual mouse-life-extension headline: the mechanism is synergistic rather than redundant. One drug clears senescent cells — the "zombie" cells that accumulate with age, secreting inflammatory signals that damage surrounding tissue. The other recalibrates metabolic signaling, essentially convincing the body it's running leaner than it is. Hit both pathways simultaneously, and the gains compound instead of cancel. Partridge was direct in her commentary: human extensions won't be 30%, but measurably healthier decades in your 80s and 90s are a realistic target if the synergy holds in clinical settings.

Human trials are now being designed. The fact that both drugs already have decades of safety data cuts years off the approval timeline.

Gobble's Take: The most exciting longevity news isn't always a new molecule — sometimes it's two old ones nobody thought to combine until now.

Source: NAD.com

The Soviet-Era Pineal Peptide That Biohackers Are Injecting to Rebuild Telomeres

It started in a Soviet gerontology lab in the 1970s. Researchers at the St. Petersburg Institute of Bioregulation isolated a short peptide chain from the pineal gland — the brain region that governs circadian rhythm and hormonal timing — and called it Epitalon. For decades it sat largely outside Western longevity circles. Now it's one of the most-discussed compounds in biohacking forums, and the reason is specific: animal studies show it can measurably lengthen telomeres, the protective caps on chromosome ends that shorten with every cell division and serve as one of the most reliable biological clocks we have.

The protocol that's circulated isn't casual. Serious users inject 10–20mg subcutaneously over a 10–20 day cycle, twice per year, often stacking it with NAD+ precursors and growth hormone secretagogues like Ipamorelin. The rationale is layered — Epitalon appears to reduce epigenetic noise, stabilize melatonin and cortisol patterns, and upregulate telomerase, the enzyme responsible for telomere maintenance. Small human pilot data and self-reported telomere tests from users have shown measurable lengthening after cycles, though no large randomized trial has confirmed this yet. It is not FDA-approved, and the research base remains thin by clinical standards.

That caveat matters — but so does the mechanism. Telomere length isn't a soft biomarker; it's directly tied to cellular aging and cancer risk.

Gobble's Take: When Soviet gerontologists and Silicon Valley biohackers land on the same molecule independently, it's probably worth understanding before dismissing.

Source: Forj Substack

mTOR: The Most Replicated Longevity Target in Science Still Has Room to Surprise You

Rapamycin has extended lifespan in every major animal model tested — mice, flies, worms, yeast — by an average of 26%, rivaling caloric restriction, the longest-standing longevity intervention we know. That's not one lab's finding; it's been replicated across strains, sexes, and species over three decades. And yet most people optimizing for longevity haven't touched it, largely because the mechanism sounds intimidating: inhibiting mTOR, a master nutrient-sensing pathway that, when chronically overactivated by modern caloric excess, accelerates cellular aging across virtually every tissue type.

The picture is more nuanced than "take rapamycin, live longer." mTOR inhibition works by restoring autophagy — the cellular housekeeping process that clears damaged proteins and organelles — and dialing back the chronic low-grade inflammation that accelerates cognitive decline, cardiovascular disease, and muscle wasting. Genetic variants matter here too: people carrying the rs2295080 TT genotype in the mTOR gene have significantly elevated baseline mTOR activity, making them likely to see larger benefits from inhibition. Human data from early trials shows improved immune function, reduced inflammatory markers, and early signals of brain health preservation. Side effects — mouth sores at higher doses, some immune suppression — are real and require clinical supervision.

Trials in elderly populations using rapamycin analogs are now scaling. The question is no longer whether mTOR inhibition works; it's how to dose it precisely enough to capture the gains without the tradeoffs.

Gobble's Take: Thirty years of replication across every organism scientists could get their hands on — if mTOR inhibition were a stock, you'd have bought it a decade ago.

Sources: Norngroup Substack · DrGlorioso Substack

AI Just Compressed a Decade of Longevity Research Into Three Years

Between 2023 and 2026, longevity research funding grew roughly tenfold, and the effect wasn't just more studies — it was a structural shift in how fast compounds move from mouse cage to clinical trial. AI-driven drug discovery platforms began scanning billions of molecular combinations at speeds no human team could match, identifying candidates like GLP-1 agonists — the drug class behind Ozempic — as dual-purpose tools: weight management on the surface, systemic inflammation reduction and potential lifespan extension underneath. Parabiosis research, once dependent on literal young-blood transfusions, got refined down to specific circulating proteins that can be isolated and administered without donors.

Fourteen distinct longevity mechanisms have now reached active clinical investigation simultaneously: telomere maintenance, mTOR inhibition, NAD+ restoration, senolytic clearance, epigenetic reprogramming, and more. Epigenetic aging clocks — algorithms trained on DNA methylation patterns — can now estimate biological age to within months, giving researchers and individuals alike a precise feedback loop that didn't exist five years ago. Rapamycin analogs are in elderly human cohorts. Senolytics have cleared phase 1 safety reviews. The pipeline is no longer theoretical.

The field produced more actionable human data between 2023 and 2026 than in the prior fifteen years combined.

Gobble's Take: Your biological age is now a number you can actually measure and move — the only question is whether you're paying attention.

Source: ClawRxiv

Quick Hits

• 30 days, 10 peptides, one very detailed diary: A biohacker documented daily injections of a ten-peptide cognitive stack — BPC-157, Semax, Selank, and seven others — logging focus improvements, mood stabilization, and zero serious adverse events across the full month. r/Biohacking
• A decade of longevity wins — and one honest frustration: Reddit's longevity community tallied the 2015–2026 scorecard: NAD+ human trials up sharply, senolytics reaching clinics, epigenetic clocks validated — but gene therapies for aging remain stuck in preclinical purgatory with no clear regulatory path forward. r/longevity

In Case You Missed It

Yesterday's top stories:

• Your Brain Tells Your Fat to Burn — Via a Hormone Called Irisin
• Precision Longevity Is Here — and It Goes Way Deeper Than Your 23andMe Results
• The Longevity Stack That Doesn't Require a Bryan Johnson Budget